HOME >> MEDICINE >> NEWS
REVLIMID(R) granted approval by FDA for treatment of multiple myeloma

Summit, N.J., June 29 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted approval for its Supplemental New Drug Application (sNDA) for an additional indication for REVLIMID (lenalidomide), for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. REVLIMID is also approved for use in the treatment of patients with transfusion-dependent anemia due to Low-or- Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Multiple myeloma is the second most common blood cancer in the United States, affecting approximately 50,000 people. About 14,600 new cases of multiple myeloma are diagnosed each year and about 12,000 Americans are expected to die of multiple myeloma in 2006. In the REVLIMID (lenalidomide)/dexamethasone treatment group, 151 patients (45%) underwent at least one dose interruption with or without a dose reduction of REVLIMID (lenalidomide) compared to 21% in the placebo/dexamethasone treatment group. Most adverse events and Grade 3 or 4 adverse events were more frequent in patients who received the combination of REVLIMID (lenalidomide)/dexamethasone compared to placebo /dexamethasone.

"The FDA approval of REVLIMID offers a new oral therapeutic option to this particular group of patients with multiple myeloma," said Graham Burton, M.D., SVP, Regulatory Affairs and Pharmacovigilance for Celgene. REVLIMID will be available in the following strengths: 5 mg, 10 mg, 15 mg, and 25 mg capsules.


'"/>

Contact: Brian P. Gill
bgill@celgene.com
908-673-9530
Weber Shandwick Worldwide
30-Jun-2006


Page: 1

Related medicine news :

1. Acrux granted first grant in Europe, triggering payment from Lilly
2. Four new us patents granted to Acrux for transdermal drug delivery
3. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
4. Sutent achieves first line EAU approval for kidney cancer
5. Breast cancer drug receives FDA approval
6. March of Dimes: Drug to prevent preterm birth needs prompt FDA approval
7. Worlds first approval of new HIV drug TMC114 provides potent new treatment option with FUZEON
8. Aussie of the Year wins approval for cervical cancer vaccine
9. UC Berkeley team helps win approval for life-saving drug for African women
10. Cincinnati Childrens applauds EU approval of rotavirus vaccine
11. TPV EU approval provides new HIV active drug to be combined with FUZEON

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2018)... ... December 06, 2018 , ... The University of ... install LED light fixtures containing Indigo-Clean continuous environmental disinfection. The lights are ... the forefront of collegiate gymnastics programs across the nation by providing this new, proven ...
(Date:12/5/2018)... DALLAS, Texas (PRWEB) , ... December 05, 2018 ... ... proved its leading SkinPen Precision device is setting a new standard as the ... Aesthetics Everything win. , Each year this award is presented at the renowned ...
(Date:12/5/2018)... ... December 05, 2018 , ... ... patient and family engagement with the use of the Precision Virtual Reality® ... provides Children’s National’s world-renowned neurosurgeons and physicians with a never-before view of ...
(Date:12/5/2018)... ... December 05, 2018 , ... Marking its seventh year, ... celebration “A Toast Heard ‘Round the World” on New Year’s Eve. Each year ... global community (alumni, students, faculty members, staff, families, and friends of the institution) to ...
(Date:12/5/2018)... Ill. (PRWEB) , ... December 05, 2018 , ... ... CRO, FSP, Strategic Resourcing, and Consulting services, announced its new office location in ... will accommodate organic growth of clinical trial operations in Europe and additional in-country ...
Breaking Medicine News(10 mins):
(Date:12/5/2018)... ... 05, 2018 , ... NDA Partners Chairman Carl Peck, ... Laboratory Integration at the United States Pharmacopeial Convention (USP), has joined the firm ... experience in domestic and international operations harmonization, compendial affairs, and the development and ...
(Date:11/29/2018)... Fla. (PRWEB) , ... November 29, 2018 , ... ... practitioner-channel dietary supplement company – announced today the launch of the Annatto-E™ product ... annatto plant (Bixa orellana). Backed by clinical research, DFH’s new Annatto-E™ products are ...
(Date:11/29/2018)... ... ... Windsor Gardens Healthcare Center of the Valley (“Windsor Gardens”), a skilled ... selected by the California Association of Health Facilities (CAHF) as only one of 20 ... California Department of Public Health awarded a grant of $700,000 to CAHF to develop ...
Breaking Medicine Technology:
Cached News: